Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus

NCT02761629 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Peg-Interferon Alpha-2A
DRUG: Ribavirin

Sponsor

Hoffmann-La Roche